Page last updated: 2024-10-16

carbamates and Obesity

carbamates has been researched along with Obesity in 18 studies

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research Excerpts

ExcerptRelevanceReference
"Dirlotapide is a microsomal triglyceride transfer protein (MTP) inhibitor developed specifically for canine weight reduction."6.44Dirlotapide: a review of its properties and role in the management of obesity in dogs. ( Gossellin, J; Sunderland, SJ; Wren, JA, 2007)
"Dirlotapide is a novel microsomal triglyceride transfer protein inhibitor intended for the treatment and management of obesity in dogs."5.12Biologic activity of dirlotapide, a novel microsomal triglyceride transfer protein inhibitor, for weight loss in obese dogs. ( Campbell, SL; Hickman, MA; King, VL; Wren, JA, 2007)
"Dirlotapide was evaluated in the management of obesity in dogs in two multicenter, clinical studies in North America."5.12Efficacy and safety of dirlotapide in the management of obese dogs evaluated in two placebo-controlled, masked clinical studies in North America. ( Campbell, SL; Eagleson, JS; Gossellin, J; King, VL; Ramudo, AA; Sunderland, SJ; Wren, JA, 2007)
" In this study, the effects of insulin glargine (IG) in combination with repaglinide or acarbose on glycemic parameters were investigated."2.74The investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese Type 2 diabetic patients. ( Duran, C; Ercan, I; Ersoy, C; Erturk, E; Guclu, M; Imamoglu, S; Kiyici, S; Selimoglu, H; Tuncel, E, 2009)
" Results were similar for both studies, and no serious adverse events were observed."2.73The safety of dirlotapide in dogs. ( Gossellin, J; Hickman, MA; Kerlin, RL; King, VL; Krautmann, MJ; Schmahai, TJ; Wren, JA, 2007)
"Dirlotapide is a microsomal triglyceride transfer protein (MTP) inhibitor developed specifically for canine weight reduction."2.44Dirlotapide: a review of its properties and role in the management of obesity in dogs. ( Gossellin, J; Sunderland, SJ; Wren, JA, 2007)
"Repaglinide is a suitable agent for first-line monotherapy in patients whose glucose metabolism cannot be optimally controlled by increasing physical activity and appropriate dietary measures."1.31[Antidiabetic drug at every meal. Repaglinide is especially recommended for slender type 2 diabetic patients]. ( Landgraf, R, 2000)

Research

Studies (18)

TimeframeStudies, this research(%)All Research%
pre-19904 (22.22)18.7374
1990's0 (0.00)18.2507
2000's9 (50.00)29.6817
2010's5 (27.78)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Zeng, Z1
Wang, L1
Ma, W1
Zheng, R1
Zhang, H2
Zeng, X1
Zhang, W1
Liu, J1
Cinar, R1
Xiong, K1
Godlewski, G1
Jourdan, T1
Lin, Y1
Ntambi, JM1
Kunos, G1
Zhao, S1
Mugabo, Y1
Ballentine, G1
Attane, C1
Iglesias, J1
Poursharifi, P1
Zhang, D1
Nguyen, TA1
Erb, H1
Prentki, R1
Peyot, ML1
Joly, E1
Tobin, S1
Fulton, S1
Brown, JM1
Madiraju, SR1
Prentki, M1
Marcus, DJ1
Zee, ML1
Davis, BJ1
Haskins, CP1
Andrews, MJ1
Amin, R1
Henderson-Redmond, AN1
Mackie, K1
Czyzyk, TA1
Morgan, DJ1
Duran, C1
Tuncel, E1
Ersoy, C1
Ercan, I1
Selimoglu, H1
Kiyici, S1
Guclu, M1
Erturk, E1
Imamoglu, S1
Geffner, ME1
Patel, K1
Miller, TL1
Hazra, R1
Silio, M1
Van Dyke, RB1
Borkowsky, W1
Worrell, C1
DiMeglio, LA1
Jacobson, DL1
SCHWARTZ, W1
Kellerer, M1
Jakob, S1
Linn, T1
Haslbeck, M1
Li, J1
Bronk, BS1
Dirlam, JP1
Blize, AE1
Bertinato, P1
Jaynes, BH1
Hickman, A1
Miskell, C1
Pillai, UA1
Tibbitts, JS1
Haven, ML1
Kolosko, NL1
Barry, CJ1
Manion, TB1
Wren, JA5
Gossellin, J3
Sunderland, SJ3
King, VL3
Krautmann, MJ1
Kerlin, RL1
Hickman, MA2
Schmahai, TJ1
Campbell, SL2
Kirk, CA1
Boucher, JF1
Ramudo, AA1
Eagleson, JS1
Landgraf, R1
Danielsson, A1
Bülow, M1
Dell, HD1
Fiedler, J1
Kamp, R1
Lorenz, D1
Blickens, DA1
Riggi, SJ1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Adolescent Master Protocol[NCT01418014]678 participants (Actual)Observational2007-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

2 reviews available for carbamates and Obesity

ArticleYear
[Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
    MMW Fortschritte der Medizin, 2003, Dec-18, Volume: 145, Issue:51-52

    Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Carbamates; Contraindications; Cyclohexanes; Diab

2003
Dirlotapide: a review of its properties and role in the management of obesity in dogs.
    Journal of veterinary pharmacology and therapeutics, 2007, Volume: 30 Suppl 1

    Topics: Animals; Anti-Obesity Agents; Carbamates; Dog Diseases; Dogs; Indoles; Obesity

2007

Trials

5 trials available for carbamates and Obesity

ArticleYear
The investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese Type 2 diabetic patients.
    Journal of endocrinological investigation, 2009, Volume: 32, Issue:1

    Topics: Acarbose; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; G

2009
The safety of dirlotapide in dogs.
    Journal of veterinary pharmacology and therapeutics, 2007, Volume: 30 Suppl 1

    Topics: Administration, Oral; Animals; Anti-Obesity Agents; Carbamates; Dog Diseases; Dogs; Female; Indoles;

2007
Biologic activity of dirlotapide, a novel microsomal triglyceride transfer protein inhibitor, for weight loss in obese dogs.
    Journal of veterinary pharmacology and therapeutics, 2007, Volume: 30 Suppl 1

    Topics: Absorptiometry, Photon; Adipose Tissue; Administration, Oral; Animals; Anti-Obesity Agents; Body Com

2007
Influence of dirlotapide, a microsomal triglyceride transfer protein inhibitor, on the digestibility of a dry expanded diet in adult dogs.
    Journal of veterinary pharmacology and therapeutics, 2007, Volume: 30 Suppl 1

    Topics: Administration, Oral; Animal Feed; Animals; Anti-Obesity Agents; Carbamates; Carrier Proteins; Diet;

2007
Efficacy and safety of dirlotapide in the management of obese dogs evaluated in two placebo-controlled, masked clinical studies in North America.
    Journal of veterinary pharmacology and therapeutics, 2007, Volume: 30 Suppl 1

    Topics: Administration, Oral; Animals; Anti-Obesity Agents; Carbamates; Dog Diseases; Dogs; Female; Indoles;

2007

Other Studies

11 other studies available for carbamates and Obesity

ArticleYear
Inhibiting the Notch signaling pathway suppresses Th17-associated airway hyperresponsiveness in obese asthmatic mice.
    Laboratory investigation; a journal of technical methods and pathology, 2019, Volume: 99, Issue:12

    Topics: Amyloid Precursor Protein Secretases; Animals; Asthma; Carbamates; Dipeptides; Disease Models, Anima

2019
Monounsaturated fatty acids generated via stearoyl CoA desaturase-1 are endogenous inhibitors of fatty acid amide hydrolase.
    Proceedings of the National Academy of Sciences of the United States of America, 2013, Nov-19, Volume: 110, Issue:47

    Topics: Amidohydrolases; Analysis of Variance; Animals; Arachidonic Acids; Benzamides; Carbamates; Endocanna

2013
α/β-Hydrolase Domain 6 Deletion Induces Adipose Browning and Prevents Obesity and Type 2 Diabetes.
    Cell reports, 2016, Mar-29, Volume: 14, Issue:12

    Topics: 3T3-L1 Cells; Adipose Tissue, Brown; Animals; Biphenyl Compounds; Carbamates; Diabetes Mellitus, Typ

2016
Mice Expressing a "Hyper-Sensitive" Form of the Cannabinoid Receptor 1 (CB1) Are Neither Obese Nor Diabetic.
    PloS one, 2016, Volume: 11, Issue:8

    Topics: Amino Acid Substitution; Animals; Body Weight; Carbamates; Diabetes Mellitus, Experimental; Dose-Res

2016
Factors associated with insulin resistance among children and adolescents perinatally infected with HIV-1 in the pediatric HIV/AIDS cohort study.
    Hormone research in paediatrics, 2011, Volume: 76, Issue:6

    Topics: Adolescent; Body Mass Index; Carbamates; CD4 Lymphocyte Count; Child; Cohort Studies; Cross-Sectiona

2011
MEBUTAMATE AND HYDROCHLOROTHIAZIDE IN HYPERTENSION.
    Journal of the American Geriatrics Society, 1964, Volume: 12

    Topics: Antihypertensive Agents; Arthritis; Arthritis, Rheumatoid; Blood Pressure Determination; Carbamates;

1964
In vitro and in vivo profile of 5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2-carboxylic acid benzylmethyl carbamoylamide (dirlotapide), a novel potent MTP inhibitor for obesity.
    Bioorganic & medicinal chemistry letters, 2007, Apr-01, Volume: 17, Issue:7

    Topics: Animals; Carbamates; Carboxylic Acids; Carrier Proteins; Chemistry, Pharmaceutical; Dogs; Drug Desig

2007
[Antidiabetic drug at every meal. Repaglinide is especially recommended for slender type 2 diabetic patients].
    MMW Fortschritte der Medizin, 2000, Jul-20, Volume: 142, Issue:28-29

    Topics: Blood Glucose; Carbamates; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dose-Response Relationship,

2000
Techniques for measuring amylase secretion from pieces of mouse pancreas.
    Analytical biochemistry, 1974, Volume: 59, Issue:1

    Topics: Amylases; Animals; Carbamates; Cholecystokinin; Choline; Dinitrophenols; Epinephrine; Evaluation Stu

1974
[Metabolism and distribution of chlorphentermine and clorofex in animal and man].
    Arzneimittel-Forschung, 1971, Volume: 21, Issue:1

    Topics: Adrenal Glands; Animals; Appetite Depressants; Biotransformation; Carbamates; Chlorphentermine; Dige

1971
Carbohydrate metabolism in normal and hyperglycemic animals treated with 1-methyl-4-(3-methyl-5-isoxazolyl)pyridinium chloride and phenformin.
    The Journal of pharmacology and experimental therapeutics, 1971, Volume: 177, Issue:3

    Topics: Animals; Blood Glucose; Carbamates; Carbohydrate Metabolism; Diabetes Mellitus; Diabetes Mellitus, E

1971